

PA Criteria	Criteria Details						
Covered Uses (FDA approved indication)	Cosentyx is an interleukin-17 (IL-17) receptor A antagonist indicated for Plaque Psoriasis (PsO), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS).						
Exclusion Criteria	Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitor (JAKis).						
Required Medical Information	Medical records supporting the request must be provided, including documentation of prior therapies and responses to treatment.						
Age Restriction	None.						
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.						
Coverage Duration	Two years. Dose will be approved according to the FDA approved labeling or within accepted standards of medical practice.						
Other Criteria/Information	Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document. <table border="1" data-bbox="496 898 1513 1045"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>J3247</td> <td>Cosentyx IV (secukinumab) 125mg/5 mL vial</td> <td>Billing unit: 1 mg 125mg/ 5mL SDV</td> </tr> </tbody> </table>	HCPCS	Description	Billing Units/How Supplied	J3247	Cosentyx IV (secukinumab) 125mg/5 mL vial	Billing unit: 1 mg 125mg/ 5mL SDV
HCPCS	Description	Billing Units/How Supplied					
J3247	Cosentyx IV (secukinumab) 125mg/5 mL vial	Billing unit: 1 mg 125mg/ 5mL SDV					

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	3/26/2025	3/26/2025	Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG)	N/A
Approved	N/A	5/15/2025	Pharmacy & Therapeutics (P&T) Committee	5/15/2025